sIL7R concentrations in the serum reflect disease activity in the lupus kidney

B R Lauwerys,^{1,2} S Nieuwland Husson,^{1,2} A L Maudoux,¹ V Badot,³
F A Houssiau^{1,2}

To cite: Lauwerys BR, Husson SN, Maudoux AL, *et al.* sIL7R concentrations in the serum reflect disease activity in the lupus kidney. *Lupus Science & Medicine* 2014;**1**:e000036. doi:10.1136/lupus-2014-000036

► Additional material is available. To view please visit the journal online (<http://dx.doi.org/10.1136/lupus-2014-000036>).

Received 16 May 2014
Accepted 24 June 2014

CrossMark

¹Pôle de pathologies rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium

²Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium

³Service de Rhumatologie, Hôpital Erasme, Brussels, Belgium

Correspondence to
Professor B R Lauwerys;
Bernard.Lauwerys@uclouvain.be

ABSTRACT

Objectives: Evaluation of disease activity in systemic lupus erythematosus (SLE) nephritis is a challenge, and repeated renal biopsies are usually needed in order to confirm a suspicion of flare. In a previous cross-sectional study, we reported that serum soluble form of the interleukin-7 receptor (sIL7R) levels is strongly associated with nephritis in SLE patients. In the present study, we wanted to confirm the association between changes in serum sIL7R concentrations and renal disease activity in a large longitudinal cohort of SLE nephritis patients.

Methods: Sera were harvested longitudinally in 105 SLE nephritis patients. Serum sIL7R cut-off value for the detection of SLE nephritis activity was determined as the mean sIL7R concentration in non-nephritis SLE patients + 2 SDs using data collected in our previous study. Patients with glomerular filtration rate (GFR) <60 mL/min/1.73 m² (n=17) were excluded from the study due to persistently elevated serum sIL7R values.

Results: Serum sIL7R concentrations above the renal cut-off value were observed in 25 (out of 88) patients with a normal GFR. These patients had significantly higher serum double-stranded DNA (dsDNA) Ab and urinary protein to creatinine (UPC) ratio. Strikingly, 12 of them developed a renal British Isles Lupus Assessment Group index (BILAG) A within the next 3 months, while this was only the case in four out of the 63 other patients (p<0.0001). The test had 75.0% sensitivity and 81.9% specificity for the detection of a renal BILAG A. Combination of serum sIL7R with any of the classical tests (anti-dsDNA Ab titres, UPC ratio, serum C3) resulted in an increased specificity for the detection of a renal flare. Administration of immunosuppressive therapy resulted in a significant decrease in serum sIL7R concentrations.

Conclusions: Serum sIL7R is a sensitive and specific marker of renal disease activity in SLE. Elevated serum sIL7R values in SLE patients are associated with or predict the occurrence of an SLE nephritis flare.

INTRODUCTION

Glomerulonephritis is a severe complication of systemic lupus erythematosus (SLE) which occurs in 30%–50% of patients. Most renal manifestations of SLE are caused by the deposition of double-stranded DNA

KEY MESSAGES

- Serum sIL7R is a sensitive and specific marker of renal disease activity in SLE.
- Combination of sIL7R with any of the classical tests (anti-dsDNA titres, UPC ratio, serum C3) results in an increased specificity for the detection of a renal flare.
- Elevated serum sIL7R values decrease upon administration of immunosuppressive therapy.

(dsDNA) antibodies in the glomeruli (either trapped as DNA–anti-dsDNA immune complexes or bound to repetitive DNA-like structures in the glomerular basement membrane), where they activate complement and initiate an inflammatory response.¹ The diagnosis of SLE nephritis is to be considered in patients with an abnormal urinalysis (proteinuria, but also haematuria, pyuria or urinary casts), increased dsDNA antibody titres and, in the most severe cases, impaired renal function. In such patients, a renal biopsy is performed in order to confirm the diagnosis and guide therapeutic decisions. Unfortunately, a significant number of patients may present several flares of glomerulonephritis during the course of the disease^{2 3} and, most of the time, each relapse requires a repeat-renal biopsy, as a ‘gold standard’ diagnostic procedure.

The reason why renal biopsies are needed for the diagnosis of SLE nephritis is mainly related to the lack of specificity of current biological markers for active renal disease in the context of the disease. Thus, increased proteinuria is a hallmark of active lupus nephritis, but can also reflect glomerular damage, or pre-eclampsia. Haematuria and pyuria have a low specificity, while the presence of casts has a low sensitivity. Serum dsDNA antibody titres increase and serum C3 concentrations decrease in patients with active renal disease, but the specificity of these observations is too low to translate into therapeutic guidelines.^{4 5}

We recently found that a soluble form of the interleukin-7 receptor (sIL7R) is produced in the lupus kidney.⁶ In vitro experiments indicated that sIL7R production is induced upon stimulation by pro-inflammatory cytokines, in particular tumour necrosis factor α (TNF α).⁷ In a cross-sectional study, including healthy controls and SLE patients, with and without nephritis, we demonstrated that high serum sIL7R values discriminate patients with nephritis from other patients and controls, and correlate with systemic lupus erythematosus disease activity index (SLEDAI) scores. In the present study, we wanted to validate the diagnostic value of serum sIL7R measurements for the detection of active SLE nephritis in a longitudinal cohort of SLE nephritis patients followed at a single centre. Our results indicate that elevated serum sIL7R concentrations are associated or predict the occurrence of a renal flare in SLE and are of great value to better select patients in which a renal biopsy is warranted.

PATIENTS AND METHODS

Patients and samples

In all, 105 patients with SLE nephritis were included in this study. All patients met the 1982 revised criteria for the classification of SLE.⁸ Demographic and renal characteristics of the patients are displayed in table 1. From July 2012, serum and urine samples were harvested in all patients after each visit at our lupus clinic, and stored at -80° . At the time of the present study, median number of samples/patient was 3 (range 1–7); median total follow-up after the first sample was 15 months (range 1–19); and median interval between visits was 5 months (range 2–14). The study was approved by the ethics committee of the Université catholique de Louvain, and informed consent was obtained from all patients.

sIL7R measurements and indices of disease activity

sIL7R serum concentrations were determined by sandwich ELISA in serum and urine samples, as previously described,⁷ using a goat polyclonal hIL7R antibody (Sigma-Aldrich) as coating antibody and a mouse monoclonal hIL7R antibody as detecting antibody (Sigma-Aldrich). The sensitivity of the ELISA is 20 pmol/mL. The presence of IL7 does not interfere with sIL7R detection. Normal range of serum sIL7R concentrations (<505 pmol/mL) was determined based on measurements made in a control population (mean $\pm$ 2 SDs), and published earlier.⁷ Similarly, serum sIL7R cut-off value for the detection of SLE nephritis activity was determined as the mean sIL7R concentration in non-nephritis SLE patients + 2 SDs (<1042 pmol/mL) using data collected in our previous study.⁶ Patients with a glomerular filtration <60 mL/min/ 1.73 m², yet inactive disease (n=17), have significantly higher serum sIL7R values, compared with patients with a glomerular filtration >60 mL/min/ 1.73 m² in the same situation (see online supplementary figure 1). Patients with abnormal

Table 1 Demographic and renal characteristics of the patients at inclusion

F/M	99/6
Mean age ($\pm$ SEM)	37.4 $\pm$ 10.7
N patients with no previous renal BILAG A	6
N patient with one previous renal BILAG A	69
N patients with two previous renal BILAG A	25
N patients with three or more previous renal BILAG A	5
Renal histology during the previous flares	
Class II	4
Class III	22 (2 of whom also had class V)
Class IV	77 (4 of whom also had class V)
IV (G)	26
IV (S)	22
IV (not determined)	29
Class V	9
No biopsy	16
Patients with GFR <60 mL/min	17

BILAG, British Isles Lupus Assessment Group index.

kidney function were therefore discarded from the subsequent analyses. Urinary sIL7R values were normalised using creatine concentrations in the same samples.

Anti-dsDNA antibody (Ab) titres (Farr assay), urinary protein to creatine (UPC, expressed in mg/mg) ratios in spot urine specimens, serum C3 concentrations, glomerular filtration rates and clinical data were retrieved from the patients' records at the same time as sIL7R measurements. All clinical and laboratory data were generated at the same site.

Active renal disease was defined as the presence of a renal British Isles Lupus Assessment Group index (BILAG) A, according to the BILAG 2004 index definition, namely, two of more of the following criteria have to be present, provided (1), (4) or (5) is included: (1) deteriorating proteinuria (severe) defined as (a) urine dipstick increased by ≥ 2 levels; (b) 24 h urine protein rising from <0.20 g to >1 g; (c) 24 h urine protein rising from >1 g by $\geq 100\%$; (d) newly documented 24 h urine protein of >1 g; (e) UPC ratio rising from <20 mg/mmol to >100 mg/mmol; (f) UPC ratio rising from >100 mg/mmol by $\geq 100\%$; (g) newly documented UPC ratio of >100 mg/mmol; (h) urine albumin to creatine ratio rising from <20 mg/mmol to >100 mg/mmol; (i) urine albumin creatine ratio rising from >100 mg/mmol by $\geq 100\%$; or (j) newly documented urine albumin to creatine ratio of >100 mg/mmol; (2) accelerated hypertension; (3) deteriorating renal function (severe) defined as (a) plasma creatine >130 μ mol/l and having risen to $>130\%$ of previous value; (b) glomerular filtration rate (GFR) having fallen to $<67\%$ of previous value; or (c)

Figure 1 Biological indices of disease activity in a longitudinal cohort of SLE nephritis patients according to serum soluble form of the interleukin-7 receptor (sIL7R) concentrations.

Anti-double-stranded DNA antibodies (A), urinary protein to creatine (UPC) ratio (B) and serum C3 (C) are plotted in patients with serum sIL7R concentrations above (sIL7R high, n=25) or below the renal cut-off (sIL7R low, n=63). p Values by Mann–Whitney U tests in (A) and (B), by Student's t test in (C).

GFR <50 mL/min, and last time was >50 mL/min or was not measured; (4) active urinary sediment; (5) histological evidence of active nephritis within last 3 months; and (6) nephrotic syndrome.⁹

Statistical analyses

Data are expressed as mean ($\pm$ SEM, unless stated differently) or median (range) and were analysed using Graphpad Prism V.4.00 software. Student's t test was used to compare variables with a normal distribution, and non-parametric tests (Mann–Whitney U or Wilcoxon matched-pairs signed rank tests) for variables not distributed normally. For regression analyses, Spearman's correlation coefficients were calculated. A p value <0.05 was considered statistically significant. Receiving operator characteristic (ROC) curves were built in order to demonstrate the variations in sensitivity and specificity of increasing cut-off values for serum sIL7R and C3 concentrations, serum anti-dsDNA antibody titres and UPC ratio, used for the detection of a renal BILAG A. ROC curves were also built in order to demonstrate the effect of the combination of sIL7R with any of the three other tests for the detection of a renal BILAG A. In this case, a test was considered positive if the result of the test is above (or below in the case of serum C3) the increasing cut-off values, and if serum sIL7R is above 1042 pmol/mL (ie, the 'renal' sIL7R cut-off value).

RESULTS

Out of 88 SLE nephritis patients with a normal kidney function, 25 had serum sIL7R measurements above the renal cut-off value during longitudinal follow-up. In these patients, mean $\pm$ SEM sIL7R concentration was 1678 $\pm$ 160 versus 508 $\pm$ 40 pmol/mL in the other patients. Patients with sIL7R serum concentrations above the renal cut-off had significantly higher dsDNA antibody titres and UPC ratios at that time point compared with the other patients (figure 1A and B). Serum C3 concentrations were lower in patients with serum sIL7R values

above the renal cut-off, but the difference did not reach statistical significance (figure 1C).

Serum sIL7R values correlated with SLEDAI scores (Pearson $r=0.48$, $p<0.0001$). Strikingly, 12 out of the 25 patients with serum sIL7R levels above the renal cut-off developed a renal BILAG A (seven International Society of Nephrology/Renal Pathology Society class IV(G), two class IV(S) and three class III kidney biopsies) at the time of or within the next 3 months following the abnormal measurement, while this was only the case in four (one class IV(G), two class IV(S), one had no biopsy) out of the 63 other patients ($p<0.0001$ by Fisher's exact test) (figure 2).

Out of the patients with a serum sIL7R value above the renal cut-off, four also had a general, two had a mucocutaneous and one had a neurological BILAG A, in addition to the renal BILAG A (table 2). In patients with serum sIL7R below the renal cut-off, five had a musculo-skeletal, one had a general and one had a mucocutaneous BILAG A during the course of the study. There was no association between sIL7R serum levels and any of these manifestations (data not shown). ROC curves showing the evolution of sIL7R sensitivity and specificity at different cut-off values for the detection of a renal BILAG A are depicted in figure 3. As shown in the same figure, the detection of serum sIL7R concentrations above the renal cut-off improved the specificity of serum dsDNA antibody titres, serum C3 concentrations or UPC ratios for the detection of a renal BILAG A. The diagnostic metrics of the tests are recapitulated in table 3.

In patients with serum sIL7R concentrations above the renal cut-off, administration of immunosuppressive therapy resulted in a significant decrease in serum sIL7R concentrations, while this was not the case in patients with serum sIL7R concentrations higher than the renal cut-off, not receiving any additional treatment (figure 4).

Finally, low urinary sIL7R concentrations were found in a majority of patients. There was no correlation between serum sIL7R and normalised urinary sIL7R

Figure 2 Serum soluble form of the interleukin-7 receptor (sIL7R) longitudinal measurements in 88 patients with SLE nephritis. sIL7R serum concentrations are depicted in patients who will (A) ($n=16$) versus will not (B) ($n=72$) present a renal BILAG A during the time of the study. The time interval between two measurements is represented as an arbitrary unit, and varies between 2 and 14 (median 5) months. The dashed line represents the renal cut-off value for sIL7R serum concentrations (1042 pmol/mL).

concentrations measured at the same time points. Patients with a renal BILAG A did not display higher urinary sIL7R values compared with the other patients. There was a modest, albeit significant, correlation between normalised sIL7R concentrations and UPC ratios (Pearson $r=0.27$, $p<0.0001$).

DISCUSSION

In a previous study, we performed cross-sectional sIL7R measurements in sera of patients with and without active lupus nephritis, and found that elevated sIL7R values have a high sensitivity and specificity for kidney involvement in SLE.⁶ In the present study, we wanted to

Table 2 Clinical and biological characteristics of 25 (out of 88) SLE nephritis patients with serum sIL7R concentrations above the renal cut-off

Age	Gender	sIL7R (pmol/mL)	dsDNA Ab titres (U/mL)	Serum C3 (mg/dL)	UPC ratio	Disease status
26	F	4587	167	50	2.0	Renal BILAG A
26	M	3035	32.5	68	1.3	Renal and mucocutaneous BILAG A
46	F	2658	289	46	5.4	Renal BILAG A, 1 month later
44	F	2241	125	60	0.9	Renal and neurological BILAG A, 2 months later
49	F	2232	43.8	89	0.2	Renal BILAG D
47	F	2220	110.7	81	0.13	Renal BILAG A, 3 months later
56	M	2119	24.8	150	0.2	Renal BILAG C
27	F	1810	7.5	90	0.3	Renal BILAG C
29	F	1803	67	65.8	0.1	Renal BILAG D
27	F	1647	158.5	47	0.8	Renal BILAG B
41	F	1636	1520	57	2.1	Renal, mucocutaneous and general BILAG A
43	F	1557	5.3	97	0.2	Renal BILAG D
51	F	1495	38.7	134	0.6	Renal BILAG D
47	F	1466	5.9	101	0.2	Renal BILAG D
28	F	1348	255	69	2.1	Renal and general BILAG A, 1 month later
33	F	1291	161	53	1.9	Renal BILAG A
24	F	1175	7	124	0.1	Renal BILAG B
19	F	1155	179	62	0.17	Renal and general BILAG A
62	F	1156	6.3	96	0.05	Renal BILAG D
50	F	1154	7	61	0.1	Renal BILAG C
28	F	1148	2092	74	2.8	Renal and general BILAG A, 2 months later
31	F	1128	16.3	52	0.1	Renal BILAG C
61	F	1110	57	6	0.1	Renal BILAG D
47	F	1109	67.4	106	0.5	Renal BILAG A, 3 months later
25	F	1088	6.2	114	5.6	Renal and general BILAG A

sIL7R, soluble form of the interleukin-7 receptor; UPC, urinary protein to creatinine.

Figure 3 Receiving operator characteristic (ROC) curves displaying the performances of serum soluble form of the interleukin-7 receptor (sIL7R) (A), serum anti-double-stranded DNA antibodies (B), serum C3 (C) and urinary protein to creatine (UPC) (D) measurements for the detection of a renal BILAG A in a cohort of SLE nephritis patients. The left panels show the variations in sensitivity and specificity of the indicated test according to several cut-off values. The dot surrounded by a circle corresponds to the cut-off values generally used for these tests (serum sIL7R=1042 pmol/mL; anti-double-stranded DNA antibodies=50 U/mL; serum C3=85 mg/dL; UPC ratio=0.5). The right panels show the ROC curves of the same tests (several cut-off values), when associated with the necessity of having a serum sIL7R value above the renal cut-off, for the detection of a renal BILAG A.

confirm the association between serum sIL7R and kidney involvement in SLE in a prospective cohort of patients followed at a single centre. Our results confirm a strong association between serum sIL7R and renal disease activity in lupus patients. When the occurrence of a renal BILAG A is used to define active renal disease in SLE, serum sIL7R concentrations have an elevated negative predictive value (93.6%) and a 48.0% positive predictive value for the detection of active renal disease.

Our interest in serum sIL7R measurements originates from our observations in synovial tissue and serum samples from patients with rheumatoid arthritis

(RA).^{10 11} We found that IL7R mRNA is induced in synovial fibroblasts upon stimulation with pro-inflammatory cytokines, such as TNF α , IL1 β or IL17. We demonstrated that fibroblasts have the ability to generate a splice variant of the IL7R mRNA, which lacks the transmembrane domain of the receptor, thereby resulting in the production of a secreted form of the molecule. In RA patients, sIL7R serum concentrations are higher than in controls, and very high values are associated with poor response to (methotrexate and TNF-blocking) therapy, probably because they reflect very active inflammatory processes in the synovium.⁷

Table 3 Metrics of the diagnostic performances of serum sIL7R concentrations, serum dsDNA Ab titres, serum C3 concentrations and UPC ratios for the detection of a renal BILAG A in a cohort of SLE nephritis patients

	sIL7R>1042 pmol/mL	dsDNA Ab titres>50 U/mL	sIL7R>1042 pmol/mL and dsDNA Ab titres>50 U/mL	UPC>0.5	sIL7R>1042 pmol/mL and UPC>0.5	serum C3<85 mg/dL	sIL7R>1042 pmol/mL and serum C3<85 mg/dL
True positive	12	12	10	14	10	13	9
True negative	59	55	69	65	71	41	67
False positive	13	17	3	7	1	31	5
False negative	4	4	6	2	6	3	7
Sensitivity (CI)—%	75.0 (47.4 to 91.6)	75.0 (47.4 to 91.7)	62.5 (35.8 to 83.7)	87.5 (60.4 to 97.8)	62.5 (35.8 to 83.7)	81.2 (53.7 to 95.0)	56.2 (30.5 to 79.2)
Specificity (CI)—%	81.9 (70.7 to 89.7)	76.4 (64.6 to 85.2)	95.8 (87.5 to 98.9)	90.3 (80.4 to 95.7)	98.6 (91.5 to 99.9)	56.9 (44.8 to 68.4)	93.0 (83.7 to 97.4)
Predictive positive value (CI)—%	48.0 (28.3 to 68.2)	41.4 (24.1 to 60.9)	76.9 (46.0 to 93.8)	66.7 (43.1 to 84.5)	90.9 (57.1 to 99.5)	29.5 (17.2 to 45.4)	64.3 (35.6 to 86.0)
Predictive negative value (CI)—%	93.6 (83.7 to 97.9)	93.2 (82.7 to 97.8)	92.0 (82.8 to 96.7)	97.0 (88.7 to 99.4)	92.2 (83.2 to 96.8)	93.2 (80.3 to 98.2)	90.5 (80.9 to 95.8)
Positive value (CI) %	4.15 (2.35 to 7.32)	3.18 (1.92 to 5.25)	15 (4.65 to 48.4)	9 (4.35 to 18.6)	45 (6.2 to 327)	1.89 (1.32 to 2.69)	8.1 (3.13 to 20.9)
Negative likelihood ratio	0.30 (0.13 to 0.71)	0.33 (0.14 to 0.77)	0.39 (0.21 to 0.73)	0.14 (0.04 to 0.51)	0.38 (0.04 to 0.18)	0.33 (0.12 to 0.93)	0.47 (0.27 to 0.82)

dsDNA, double-stranded DNA; sIL7R, soluble form of the interleukin-7 receptor; UPC, urinary protein to creatinine.

Figure 4 Evolution of elevated serum soluble form of the interleukin-7 receptor (sIL7R) concentrations in follow-up sera. Out of 25 patients with serum sIL7R values above the renal cut-off, 19 had at least one follow-up measurement (median follow-up: 3 months). Eight of them received immunosuppressive therapy for their renal BILAG A (A), and 11 did not (B). p Values by Wilcoxon matched-pairs signed rank test.

SLE patients are characterised by a type I interferon gene expression bias, at least in their peripheral blood mononuclear cells (PBMC) and joints. However, the presence of pro-inflammatory cytokines, such as TNF α , was documented in kidney sections of patients with active lupus nephritis.¹² In addition, the pathogenic role of TNF α in the local inflammatory process was demonstrated by the strong inhibitory effect of TNF blockade on proteinuria in patients with refractory disease (admittedly at the cost of very serious infectious side effects).¹³ In a previous study, we showed that non-nephritis SLE patients display slightly higher sIL7R serum levels compared with controls. By contrast, sIL7R serum levels in patients with active SLE nephritis are much higher, enabling a clear-cut discrimination between SLE nephritis and non-nephritis patients. sIL7R mRNA expression itself is not higher in PBMC from patients with SLE nephritis, which indicates that the presence of the protein in the serum does not reflect systemic disease activity. Accordingly, we found positive immunohistochemistry signals for IL7R and TNF α in kidney sections from patients with active renal lupus. The concentration of the IL7R signal in perivascular cells probably explains the preferential secretion of the soluble form of the protein in blood.⁶ sIL7R is also found in urine, but given the significant association between urinary sIL7R concentrations and UPC ratios, it is probable that the presence of the protein in urinary samples is due to glomerular leakage, rather than active secretion.

With such a strong predictive negative value, and a predictive positive value of 48.0% for the occurrence of a renal BILAG A, serum sIL7R measurements appear to be a helpful tool for the clinical follow-up of patients with SLE. Elevated serum concentrations of the protein are a strong signal that kidney inflammation might be present, requiring closer follow-up and evaluation of the

need for a kidney biopsy. Of note, 52% of patients with serum sIL7R concentrations above the renal cut-off do not develop a renal BILAG A. In many of them, low grade proteinuria (UPC between 0.2 and 1), elevated dsDNA antibody titres or decreased serum C3 is compatible with grumbling disease, and long-term follow-up of these patients will be of interest to assess increased disease activity or modifications in renal function in the future. Long-term follow-up will also indicate whether the few patients (three out of 25) with elevated serum sIL7R, yet low dsDNA antibody titres, normal C3 and UPC <0.2, are genuine false positives.

In this perspective, it should be stressed that our definition of a renal flare, based on the observation of a renal BILAG A, is potentially restrictive, and could result by itself in an underestimation of the specificity of serum sIL7R as a marker of renal disease activity in SLE. There are several clinical definitions of a renal flare available in SLE, which result in different categorisations of the patients, but there is no gold standard. We believe that a renal BILAG A score truly reflects renal disease activity in our series, since 15 out of the 16 patients falling under that category received new or additional immunosuppressive therapy at that time; one patient did not receive additional treatment because the renal flare was due to lack of compliance to therapy.

Several candidate biomarkers are presently under scrutiny as markers of disease activity in SLE nephritis. The most promising candidates are measured in urine samples; thus, urinary TNF-like inducer of apoptosis (TWEAK),¹⁴ monocyte chemoattractant protein-1¹⁵ or neutrophil gelatinase-associated lipocalin^{15–16} concentrations were shown in several studies to associate with clinical or histological markers of disease activity, or even predict the occurrence of a flare of the disease. The absence of significant correlations between urinary concentrations of these markers and proteinuria suggest that their presence in the urine is due to an active secretion process rather than glomerular leakage. Several serum markers were suggested to be associated with disease activity in the lupus kidney, but the described associations were either not consistent or not validated in independent studies.

In our series, UPC ratio is a very good marker for the detection of active renal disease, but there is some circularity here, since either newly documented or rising proteinuria is part of the definition of a renal BILAG A score. Systemic markers of disease activity (anti-dsDNA antibodies, serum C3) also show very good performances for the detection of renal flares, which is not surprising in this cohort of patients who were selected for the presence of renal disease. However, it is known that these markers are not specific to kidney involvement in SLE, by contrast to serum sIL7R.⁶ In addition, despite the very favourable context in which the performance of these systemic markers of disease activity is evaluated, combination of any of them with the presence of elevated serum sIL7R concentration still increases their specificity for the detection of a renal BILAG A. This can be very useful in

doubtful situations (eg, a pregnant woman with high dsDNA antibody titres, low serum C3, increased UPC ratio, yet low serum sIL7R concentrations has a very low probability of developing a renal BILAG A flare, according to our results). In the future, it is probable that such combination of two or more markers in decision matrices will be routinely used in the clinical care of patients with complex disease manifestations.

In conclusion, our results indicate that serum sIL7R is a good marker of disease activity in SLE nephritis, as it is produced locally upon stimulation by pro-inflammatory cytokines. Elevated serum sIL7R concentrations (in SLE patients with a normal kidney function) increase the probability of a (pending) renal flare. By contrast, sIL7R concentrations below the renal cut-off are associated with a very low probability of active renal disease.

Contributors BL, VB and FH designed the study; BL, SNH, ALM collected the experimental data, BL, VB and FH interpreted the data, BL and FH wrote the manuscript.

Funding This work was supported by grants from the Fonds de la Recherche Scientifique et Médicale (FRSM—Communauté française de Belgique) and Cap48 (charity supported by the Radio Télévision belge francophone).

Competing interests None.

Patient consent Obtained.

Ethics approval Comité d'éthique biomédicale hospitalo-facultaire de l'Université catholique de Louvain.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All the laboratory data are available on request to the corresponding author.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Hahn BH. Antibodies to DNA. *N Engl J Med* 1998;338:1359–68.
2. Houssiau FA. Toward better treatment for lupus nephritis. *N Engl J Med* 2011;365:1929–30.
3. Houssiau FA, Lauwerys BR. Current management of lupus nephritis. *Best Pract Res Clin Rheumatol* 2013;27:319–28.
4. Ter Borg EJ, Horst G, Hummel EJ, *et al.* Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. *Arthritis Rheum* 1990;33:634–43.
5. Bootsma H, Spronk P, Derksen R, *et al.* Prevention of relapses in systemic lupus erythematosus. *Lancet* 1995;345:1595–9.
6. Badot V, Luijten RK, van Roon JA, *et al.* Serum soluble interleukin-7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus. *Ann Rheum Dis* 2013;72:453–6.
7. Badot V, Durez P, Van den Eynde BJ, *et al.* Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines. *J Cell Mol Med* 2011;15:2335–42.
8. Tan EM, Cohen AS, Fries JF, *et al.* The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271–7.
9. Isenberg DA, Rahman A, Allen E, *et al.* BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. *Rheumatology (Oxford)* 2005;44:902–6.
10. Nzeusseu Toukap A, Galant C, Theate I, *et al.* Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. *Arthritis Rheum* 2007;56:1579–88.

11. Badot V, Galant C, Nzeusseu Toukap A, *et al.* Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. *Arthritis Res Ther* 2009;11:R57.
12. Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. *Hum Pathol* 1995;26:558–64.
13. Aringer M, Houssiau F, Gordon C, *et al.* Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. *Rheumatology (Oxford)* 2009;48:1451–4.
14. Schwartz N, Rubinstein T, Burkly LC, *et al.* Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. *Arthritis Res Ther* 2009;11:R143.
15. Brunner HI, Bennett MR, Mina R, *et al.* Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. *Arthritis Rheum* 2012;64:2687–97.
16. Brunner HI, Mueller M, Rutherford C, *et al.* Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. *Arthritis Rheum* 2006;54:2577–84.